데이터가 없습니다.

1. Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type Mycobacterium avium complex pulmonary disease in relation to sputum smear results: a retrospective cohort study [ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ] - 2023.11.15
2. Stratification of Nontuberculous Mycobacterial Disease Risk in Type 2 Diabetes Based on Metformin Use: a Population-Based Cohort Study in South Korea. [ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ] - 2023.06.15
3. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use. [ Microbiology spectrum ] - 2023.06.15
4. Type 2 Diabetes Mellitus- and Complication-Related Risk of Nontuberculous Mycobacterial Disease in a South Korean Cohort. [ Microbiology spectrum ] - 2023.03.28
5. Radiologic Subtypes and Treatment Outcome of Unclassifiable Type Mycobacterium avium Complex Pulmonary Disease [ JOURNAL OF KOREAN MEDICAL SCIENCE ] - 2023.01.06
6. Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease [ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ] - 2022.12.20
7. Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio According to the Radiologic Severity of Mycobacterium avium Complex Pulmonary Disease [ JOURNAL OF KOREAN MEDICAL SCIENCE ] - 2022.10.17
8. Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease [ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ] - 2022.09.20
9. Treatment outcomes of the interstitial lung disease subtype of unclassifiable type Mycobacterium avium complex pulmonary disease [ JOURNAL OF INFECTION AND CHEMOTHERAPY ] - 2022.08.01
10. Treatment outcome of continuation of intravenous amikacin for Mycobacterium abscessus pulmonary disease with a persistent culture positivity after the treatment initiation [ JOURNAL OF INFECTION AND CHEMOTHERAPY ] - 2022.08.01
11. Drug-level change and optimal dose adjustment of tacrolimus with the use of rifabutin for treating mycobacterial disease in solid organ transplant recipients [ Transplant Infectious Disease ] - 2022.08.01
12. The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea [ JOURNAL OF KOREAN MEDICAL SCIENCE ] - 2022.04.11
13. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types [ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ] - 2022.02.15
14. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea [ BMC GASTROENTEROLOGY ] - 2021.10.20
15. Redevelopment after spontaneous sputum conversion in noncavitary nodular bronchiectatic Mycobacterium avium complex lung disease [ JOURNAL OF INFECTION AND CHEMOTHERAPY ] - 2021.08.01
16. Prediction of 1-year treatment outcome using early sputum culture conversion status in Mycobacterium abscessus pulmonary disease [ JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE ] - 2021.06.01
17. Cavity formation and its predictors in noncavitary nodular bronchiectatic Mycobacterium avium complex pulmonary disease [ RESPIRATORY MEDICINE ] - 2021.04.01
18. Changes in chest X-ray findings in 1-and 2-month group after treatment initiation for suspected pulmonary tuberculosis [ KOREAN JOURNAL OF INTERNAL MEDICINE ] - 2020.09.01
19. Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: A propensity score analysis [ JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE ] - 2020.09.01
20. Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection [ PLOS ONE ] - 2020.06.16
21. Spontaneous sputum conversion and reversion in Mycobacterium abscessus complex lung disease. [ PLoS One ] - 2020.04.27
22. Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in Mycobacterium avium Complex Lung Disease [ JOURNAL OF KOREAN MEDICAL SCIENCE ] - 2020.03.09
23. Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease [ JOURNAL OF THORACIC DISEASE ] - 2020.03.01
24. Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea [ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ] - 2019.12.15
25. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers [ RESPIRATORY MEDICINE ] - 2019.10.15
26. Long-Term Outcomes of Adult Lung Transplantation Recipients: A Single-Center Experience in South Korea [ Tuberculosis and Respiratory Diseases(결핵 및 호흡기질환) ] - 2019.10.01
27. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease. [ CLINICAL INFECTIOUS DISEASES ] - 2019.05.17
28. The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease [ RESPIRATORY MEDICINE ] - 2019.04.01
29. The second recurrence of Mycobacterium avium complex lung disease after successful treatment for first recurrence [ EUROPEAN RESPIRATORY JOURNAL ] - 2019.01.03
30. Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease [ JOURNAL OF KOREAN MEDICAL SCIENCE ] - 2018.11.19
31. Risk for cardiovascular disease in patients with nontuberculous mycobacteria treated with macrolide [ JOURNAL OF THORACIC DISEASE ] - 2018.10.01
32. The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea [ RESPIRATORY MEDICINE ] - 2018.10.01
33. In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease [ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ] - 2018.09.24
34. Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA [ PLOS ONE ] - 2018.07.05
35. Clinical characteristics and treatment outcomes of pleural effusions in patients with nontuberculous mycobacterial disease. [ RESPIRATORY MEDICINE ] - 2017.12.01
36. Frequency and Type of Disputed rpoB Mutations in Mycobacterium tuberculosis Isolates from South Korea [ Tuberculosis and Respiratory Diseases ] - 2017.07.01
37. The Impact of Emergency Adult Living-Donor Liver Transplantation on the Survival of Patients with Antituberculosis Therapy-Induced Acute Liver Failure. [ LIVER TRANSPLANTATION ] - 2017.06.01
38. Preventing the Transmission of Tuberculosis in Health Care Settings: Administrative Control. [ Tuberculosis and Respiratory Diseases(결핵 및 호흡기질환) ] - 2017.01.01
39. Analysis of discrepant results between the Genotype® MTBDRplus assay and an antimicrobial-susceptibility test for isoniazid-resistant tuberculosis [ RESPIRATORY MEDICINE ] - 2017.01.01
40. Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients with Acute Respiratory Failure: A Propensity Analysis of Mortality. [ CLINICAL INFECTIOUS DISEASES ] - 2016.12.01
41. Restrictive chronic lung function decline after haematopoietic stem cell transplantation. [ EUROPEAN RESPIRATORY JOURNAL ] - 2016.01.01
42. The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. [ INTERNATIONAL JOURNAL OF HEMATOLOGY ] - 2015.09.01
43. Lung Disease Caused by Mycobacterium malmoense in an Immunocompetent Patient. [ Tuberculosis and Respiratory Diseases(결핵 및 호흡기질환) ] - 2015.07.01
44. Risk Factors for Recurrence after Successful Treatment of Mycobacterium avium Complex Lung Disease. [ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ] - 2015.06.01
45. Massive Hemoptysis Due to Pulmonary Vein Stenosis Following Catheter Ablation for Atrial Fibrillation. [ Respiratory Care ] - 2015.03.01
46. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. [ JOURNAL OF INFECTION AND CHEMOTHERAPY ] - 2014.10.01
47. Value of Flexible Bronchoscopy for the Preoperative Assessment of NSCLC Diagnosed Using Percutaneous Core Needle Biopsy [ THORACIC AND CARDIOVASCULAR SURGEON ] - 2014.10.01
48. Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen [ RESPIRATORY MEDICINE ] - 2014.04.01

1. 치료 불응성 미코박테륨 아비움 복합체 폐질환 환자를 대상으로 경구로 투여되는 Epetraborole의 유효성과 안전성, 약동학을 평가하기 위한 제2_3상, 무작위배정, 이중눈가림, 위약 대조, 다기관, 전향적 임상시험(MACrO2) - 2022.11.17 ~ 2026.04.16
2. M. abscessus 폐질환의 치료에 각 약제의 역할 규명 - 2022.06.01 ~ 2022.12.31
3. Mycobacterium avium complex 폐질환의 재발을 예측하고 분류하는 균주인자와 유전형 분석 - 2022.03.01 ~ 2023.02.28
4. M. abscessus 폐질환의 치료에 각 약제의 역할 규명 - 2021.09.01 ~ 2022.05.31
5. (2019, 기본) Mycobacterium avium complex 폐질환의 치료반응을 예측할 수 있는 유전형 연구 - 2021.03.01 ~ 2022.02.28
6. 당뇨병과 메트포르민이 비결핵항산균폐질환 발생과 사망에 미치는 영향 건강보험심사평가원 자료 연구 - 2021.01.01 ~ 2021.12.31
7. 마이코박테리움 아비움 복합체 폐질환 환자에서 다좌위 서열 형별분석 유전형과 영상소견 관계 연구 - 2021.01.01 ~ 2021.12.31
8. Mycobacterium avium complex 폐질환의 치료반응을 예측할 수 있는 유전형 연구 - 2020.03.01 ~ 2021.02.28
9. Mycobacterium avium complex 폐질환의 치료반응을 예측할 수 있는 유전형 연구 - 2019.06.01 ~ 2020.02.29
10. 한국인 염증성 장질환 환자에서 azathioprine 및 TNF길항제 사용에 따른 결핵위험성: 건강보험심사평가원 자료 연구 - 2016.01.01 ~ 2016.12.31
11. 국내결핵환자에서 rpoB gene의 rifampicin에 대한 disputed mutation 연구 및 검출 kit의 개발 - 2015.06.15 ~ 2016.09.30
12. MTBDRplus assay와 약제감수성검사가 불일치를 보이는 폐결핵환자의 결핵균주 유전자 및 치료결과 분석 - 2015.01.01 ~ 2015.12.31
13. MTBDRplus assay와 약제감수성검사가 불일치를 보이는 폐결핵환자의 결핵균주 유전자 및 치료결과 분석 - 2014.01.01 ~ 2014.12.31

데이터가 없습니다.

      데이터가 없습니다.

 공지